Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 9Withdrawn 2Terminated 2Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Breast Neoplasms 31Lymphoma 18Lymphoma, Large B-Cell, Diffuse 17Sarcoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasm Metastasis 10Hodgkin Disease 9Lymphoma, Non-Hodgkin 8Recurrence 7Prostatic Neoplasms 7Neoplasms 7Multiple Myeloma 7Burkitt Lymphoma 7Ovarian Neoplasms 6Leukemia 6Lymphoma, B-Cell 5Fallopian Tube Neoplasms 5Cardiotoxicity 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Osteosarcoma 4Liver Neoplasms 4Triple Negative Breast Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Colonic Neoplasms 3Waldenstrom Macroglobulinemia 2

Interventions

Filgrastim 8Cyclophosphamide 8Cyclosporine 7fludarabine phosphate 6Antilymphocyte Serum 6Rituximab 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Methotrexate 5Cord Blood Stem Cell Transplantation 5Etoposide 4Busulfan 4Whole-Body Irradiation 3Methylprednisolone 3Melphalan 3Vincristine 2Tacrolimus 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Cytarabine 2Carboplatin 2Amplified Fragment Length Polymorphism Analysis 2venetoclax 1pegfilgrastim 1obatoclax 1ibritumomab tiuxetan 1fludarabine 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Dendritic Cell Sarcoma, Interdigitating × Doxorubicin × Clear all
NCT02531308 2022-09-28

DLBCL

Rush University Medical Center

Phase 2 Terminated
5 enrolled 5 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT00933985 2014-05-01

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled
DermatologicLymphoidOther hematologic neoplasmSarcoma

Blast Crisis, Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡